Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07515469CT.gov A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk | — | Not Yet Recruiting | — | — | — |
NCT07327788CT.gov QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT | — | Recruiting | — | — | — |
NCT07119931CT.gov A Clinical Study Evaluating HAIC Combined With Iparomlimab and Tuvonralimab Injection Plus Bevacizumab in Patients With Initially Potentially Resectable Hepatocellular Carcinoma (ITBHaic Study) | — | Not Yet Recruiting | — | — | — |
NCT07115550CT.gov A Single-center, Single-arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined With Regorafenib in the Treatment of Advanced Second-line or Above Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT07099274CT.gov Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT07128251CT.gov A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC) | — | Not Yet Recruiting | — | — | — |
NCT07131501CT.gov A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT06954116CT.gov Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence | — | Not Yet Recruiting | — | — | — |
NCT07014150CT.gov Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT06958484CT.gov Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatocellular Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tuvonralimab (this asset) | Tianjin Medical University Cancer Institute and Hospital | P2 | CCC · 53 |
| Adefovir | Bukwang Pharmaceutical | P4 | BBB |
| Huaier Granule | Tongji Hospital | P4 | BBB |
| Fluorouracilum | Li Qiang | P4 | BBB |
| Oxaliplatin | Li Qiang | P4 | BBB |
| Theprubicin | RWTH Aachen University | P4 | BB |
| Adriamycin | VA Office of Research and Development | P4 | BB |
| nrt6003 | Second Affiliated Hospital of Guangzhou Medical University | P3 | BB |
| Epirubicin | Fudan University | P4 | BB |
+42 more in the Hepatocellular Carcinoma cohort
Other indications for Tuvonralimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Small Cell Lung Carcinoma | — | P3 | BB · 66 |
| Autoimmune Pulmonary Disease Due To PD-1 Deficiency | — | P4 | BB · 65 |
| Melanoma | — | P4 | B · 59 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tuvonralimab in Hepatocellular Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tuvonralimab-hepatocellular-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →